Ratio Therapeutics: Funding, Investors & Team (Oct 2026)
Ratio Therapeutics, a pharmaceutical firm in the discovery to early clinical phase, uses a variety of cutting-edge technologies to provide the best-in-class tailored radiotherapeutics for the treatment of cancer. The TrilliumTM targeting scaffold from Ratio Therapeutics combines best-in-class chelation technology with pharmacokinetic modification to produce unique small molecules that can target a variety of cancer targets. Our chemicals allow for therapeutic and imaging radioisotopes, or "theranostics." Compound selection is faster and reduced in risk because to our platform's adaptability and small-scale imaging patient studies.
Ratio Therapeutics has raised $20.0M across 1 funding round on record, the most recent a Series A of $20.0M announced in Feb 2023.
That round is above the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.
Ratio Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2023.
Ratio Therapeutics Funding Rounds
Ratio Therapeutics Founders and Leadership Team
Contact details for the Ratio Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Ratio Therapeutics Funding Compared to Other Health Care Startups
Ratio Therapeutics' latest round of $20.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Ratio Therapeutics in Health Care and Boston
Companies Similar to Ratio Therapeutics
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Aptatek is developing cutting edge technologies for portable disease management devices that will improve…
Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…
Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…
For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…
Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…
Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
Ratio Therapeutics Funding FAQs
What does Ratio Therapeutics do?
Ratio Therapeutics, a pharmaceutical firm in the discovery to early clinical phase, uses a variety of cutting-edge technologies to provide the best-in-class tailored radiotherapeutics for the treatment of cancer. The TrilliumTM targeting scaffold from Ratio Therapeutics combines best-in-class chelation technology with pharmacokinetic modification to produce unique small molecules that can target a variety of cancer targets. Our chemicals allow for therapeutic and imaging radioisotopes, or "theranostics." Compound selection is faster and reduced in risk because to our platform's adaptability and small-scale imaging patient studies.
How much funding has Ratio Therapeutics raised?
Ratio Therapeutics has raised $20.0M across 1 round on record. The most recent is a Series A of $20.0M announced in Feb 2023.
When did Ratio Therapeutics last raise funding?
Ratio Therapeutics' most recent funding round on record is a Series A of $20.0M, announced in Feb 2023.
Who is the CEO of Ratio Therapeutics?
Jack Hoppin is listed as CEO at Ratio Therapeutics.
Where is Ratio Therapeutics headquartered?
Ratio Therapeutics is based in Boston, Massachusetts, United States.
How many employees does Ratio Therapeutics have?
Ratio Therapeutics is in the 1-10 employee band.
How does Ratio Therapeutics' funding compare to other Health Care startups?
Ratio Therapeutics' latest round of $20.0M is above the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.
About FundedIQ's Ratio Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Ratio Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.